CTT Pharmaceutical Holdings, Inc. has reported a significant transaction involving its CEO, Ryan Khouri. On November 12, 2026, Khouri acquired 1,500 shares of the company, demonstrating a personal investment in CTT Pharmaceutical. This acquisition could indicate his confidence in the company's direction and future performance.

CTT Pharmaceutical Holdings, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates in the OTC market under the ticker CTTH. The company is based in Tampa, Florida, and has undergone several name changes, previously known as Mindesta Inc. and Industrial Minerals Inc. CTT is categorized as a non-accelerated filer, smaller reporting company, and emerging growth company.

The recent filing details the specifics of the transaction, noting that Khouri acquired the shares at a price of $0.054 each. Following this transaction, he holds a total of 9,454,036 shares in the company. The filing states, "Transaction Code: P" indicating a purchase, and confirms that the ownership is direct.

This acquisition may have implications for CTT Pharmaceutical's stakeholders, including investors and employees, as it reflects the CEO's personal stake in the company. Such insider transactions are often viewed as a signal of confidence, potentially influencing investor sentiment.

Looking ahead, it is unclear what further actions may follow this transaction, as the filing does not specify any upcoming votes or additional filings related to this acquisition.